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Abstract 
 
Purpose: Clinical practice adherence to current guidelines that recommend primary 
prophylaxis (PP) with granulocyte-colony stimulating factors (G-CSFs) for patients at high 
(≥20%) overall risk of febrile neutropenia (FN) was evaluated. 
Methods: Adult patients with breast cancer, non-small cell lung cancer (NSCLC), small-cell 
lung cancer (SCLC), or ovarian cancer were enrolled if myelotoxic chemotherapy was 
planned and they had an investigator-assessed overall FN risk ≥20%. The primary outcome 
was FN incidence. 
Results: In total 1347 patients were analyzed (breast cancer, n=829; NSCLC, n=224; SCLC, 
 
n=137; ovarian cancer, n=157). Patients with breast cancer exhibited fewer individual FN 
risk factors than patients with other cancers, and were far more likely to have received a 
high FN–risk chemotherapy regimen. However, a substantial proportion of all patients 
(45%-80% across tumour types) did not receive G-CSF PP in alignment with investigator 
risk-assessment and guideline recommendations. FN occurred in 127 patients overall (9%, 
95%CI: 8-11%), and incidence was higher in SCLC (15%) than other tumour types (8% in 
ovarian and NSCLC, 9% in breast cancer).  A post-hoc analysis of G-CSF use indicated that 
G-CSF prophylaxis was not given within the recommended timeframe after chemotherapy 
(within 1-3 days) or was not continued across all cycles in 39% of patients. 
Conclusions: FN risk-assessment was predominantly based on clinical judgement and 
individual risk factors, and guidelines regarding G-CSF PP for patients at high FN risk were 
not consistently followed. Improved education of physicians may enable more fully-informed 
neutropenia management in patients with solid tumours. 
 
 
 
 
 
 
 
Keywords: chemotherapy, myelotoxicity, febrile neutropenia, risk assessment, 
granulocyte-colony stimulating factor, prophylaxis. 
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Introduction 
 
Febrile neutropenia (FN) is a common side-effect of myelotoxic chemotherapy, and can 
result in dose-reductions or delay to subsequent cycles of chemotherapy.(1) Reduced 
chemotherapy relative dose intensity (RDI) has been associated with poor outcomes in 
lymphoma, and breast, lung and ovarian cancer.(2–7) FN frequently requires hospitalisation, 
which is associated with substantial use of medical resources and in-hospital mortality rates 
of up to 8% in patients with solid tumours.(8–11) 
 
 
Primary prophylaxis (PP) with granulocyte-colony stimulating factors (G-CSFs; daily G-CSFs 
filgrastim and lenograstim, and once-per-cycle pegfilgrastim) reduces the incidence of FN 
and the duration of severe neutropenia.(12,13) Clinical guidelines recommend PP with G-CSFs 
for patients at high (≥20%) overall FN risk.(14-18) Patients’ overall risk should be assessed at 
the beginning of each chemotherapy cycle, using the risk associated with their planned 
regimen and individual risk-factors such as older age and advanced disease. International 
guidelines also recommend G-CSF PP to maintain chemotherapy in settings where reduced 
RDI is associated with poor outcomes.(14,15) 
 
 
IMPACT Solid was a large prospective observational study of routine clinical practice in 
Europe, Australia and Canada, designed to describe FN incidence and adherence to G-CSF 
guidelines in patients with solid tumours who had an overall physician-assessed FN risk of 
≥20% (ClinicalTrials.gov: NCT00883181). An interim analysis of data from this study was 
 
presented in abstract form at the 2009 ECCO/ESMO meeting.(19) Additional post-hoc 
 
analyses were performed to better understand the FN risk-assessment and G-CSF use in the 
study. 
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Material and methods 
 
Data regarding chemotherapy delivery, G-CSF use, and haematological toxicities were 
recorded for each patient. Centres were selected to ensure data were recorded as part of 
routine clinical practice, and to represent a variety of centres within each country. Eligible 
patients were enrolled sequentially. Upon completion of all planned chemotherapy cycles, or 
following cessation of chemotherapy for any reason, patients were followed-up annually for 
5 years or until disease progression or death. Long-term follow-up is ongoing; the current 
 
analysis reports neutropenia-related outcomes during the chemotherapy treatment period. 
 
 
 
 
Patients 
 
Patients aged ≥18 years with breast, ovarian or lung cancer, and receiving any cytotoxic 
chemotherapy were eligible if assessed by their physician to have an overall FN-risk of 
≥20%. Prior radiotherapy was permitted if it had ceased >2 weeks before commencing 
chemotherapy in the current study. 
 
 
Where required, the study protocol was approved by institutional review boards and 
patients provided written informed consent. 
 
 
Outcome measures 
 
The primary outcome was the proportion of patients experiencing FN in cycles 1–8, 
summarised by tumour type and overall G-CSF use. FN was defined as a single oral 
temperature ≥38.3˚C, or a temperature of ≥38.0˚C for ≥1 hour with a neutrophil count of 
<0.5x109/L or <1.0x109/L and predicted to fall below 0.5x109/L.(17) 
 
 
 
 
Secondary outcomes included the proportion of patients experiencing FN in cycle 1, the G- 
CSF type and number of days’ use, chemotherapy dose intensity, and use of anti-infectives. 
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G-CSF use in the study was with either pegfilgrastim or with a daily G-CSF; patients were 
allowed to receive any daily G-CSF and results for daily G-CSF were grouped together. The 
prespecified analysis of overall G-CSF use was derived programmatically, and patients were 
included in one of the following groups: 
 primary prophylaxis (PP): G-CSF initiated within days 1−7 of chemotherapy cycle 1, 
if chemotherapy dosed for ≤7 days; or within days 1–11 if dosed for >7 days. 
 secondary prophylaxis (SP): as above, with G-CSF initiated in cycle 2 or later 
 
 treatment: G-CSF initiated after day 7 in any cycle, or after day 11 if no subsequent 
prophylaxis 
 no G-CSF: no G-CSF received as either prophylaxis or treatment. 
 
Note: Prophylactic G-CSF use in a single cycle was sufficient to meet the PP/SP definitions; 
 
there was no requirement for continued prophylaxis across all subsequent cycles. 
 
 
 
 
RDI was defined as dose intensity achieved by a patient relative to their planned dose 
intensity. 
 
 
Post-hoc analyses 
 
Received chemotherapy regimens were matched to a standard “textbook” regimen. 
Textbook regimens were assigned to a FN risk category (high >20%, moderate 10%-20%, 
low <10%) based on guidelines, published references of FN rates with specific regimens and 
author review (Supplemental Table 1).  Patients who received a standard textbook regimen 
throughout the observation period remained in the respective chemotherapy FN-risk 
category; patients were assigned to the “other” category if they received a regimen that 
could not be matched to a textbook regimen or if any agent in a textbook regimen was 
reduced by >10% in cycle 1 or if the number of cycles differed from the standard regimen. 
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In a post-hoc analyses of G-CSF use, a more stringent definition of prophylaxis was applied 
that more closely matched the labelling instructions for filgrastim and pegfilgrastim.(20,21) 
Prophylactic use was defined as G-CSF initiated within 1-3 days after completing 
chemotherapy within a cycle, and for the purposes of this report we have termed this 
definition “on-schedule” prophylaxis to distinguish it from the prespecified analyses.  G-CSF 
use initiated ≥1 day after the FN event and within the same cycle was considered 
treatment/rescue use. For daily G-CSF, ≥3 days of continuous administration were required 
to be considered on-schedule prophylaxis use. 
 
 
Overall G-CSF use was analyzed applying the more stringent definitions and patients were 
included in one of the following groups: 
 on-schedule PP: prophylactic G-CSF given in cycle 1 and all subsequent cycles 
 
 not on-schedule PP: all other use of G-CSF, including secondary prophylaxis, G-CSF 
given after day 3, or G-CSF given as prophylaxis in at least one cycle but not in all 
cycles 
 no G-CSF: no G-CSF at all given in any cycle (this is the same definition as the 
prespecified analysis) 
 
 
Further analysis was conducted to characterize the G-CSF support given to patients who 
experienced an FN event using the more stringent “on-schedule” prophylaxis definitions. 
 
 
In addition, whether patients who experienced FN received G-CSF prophylaxis in the next 
cycle was determined. FN and no subsequent prophylaxis was defined as no on-schedule 
prophylactic G-CSF given in the next cycle after the first FN, regardless of prior G-CSF 
support. 
 
 
Statistical analysis 
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Sample size was chosen to allow adequate precision when estimating the proportion of 
patients achieving the primary outcome. The expected distribution across tumour types 
was: breast cancer, n=839; non-small cell lung cancer (NSCLC), n=177; small-cell lung 
cancer (SCLC), n=78; and ovarian cancer, n=206. 
 
 
All analysis was descriptive in nature and was performed on the Full Analysis Set, which 
included patients who met the protocol-specified eligibility criteria and started ≥1 
chemotherapy cycle up to a maximum of 8 cycles. Analysis was performed using Statistical 
Analysis Software (SAS®). Categorical data were summarised using the number and 
percentages of patients, with exact 95% confidence intervals (95% CI) where appropriate. 
Continuous data were summarised using means, standard deviations (SD), medians and 
interquartile ranges. 
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Results 
 
Patient disposition 
 
1347/1370 enrolled patients (98%) were included in the Full Analysis Set. Patients were 
treated between March 2007 and October 2009, at 85 centres in 11 European countries, 5 
Canadian centres and 10 Australian centres. Centres were most commonly public (56/100, 
 
56%) or university hospitals (25/100, 25%). Patients were most frequently from Poland 
 
(21%), and Australia or Italy (11% each). 
 
 
 
 
Over half the patients analysed had breast cancer (n=829, 62%) [Figure 1]. Distribution of 
patients across the other tumour types was: NSCLC n=224 (17%); SCLC, n=137 (10%); 
and ovarian, n=157 (12%). 
 
 
Among all patients, 79% (1069/1347) completed all planned chemotherapy cycles; breast 
cancer patients had the highest proportion of chemotherapy completion (Figure 1). The 
most common reasons for non-completion overall were disease progression (94/278, 34%) 
and non-haematological adverse events (55/278, 20%), with similar results across tumour 
types. 
 
 
Patient demographics by tumour type 
 
Breast cancer patients generally exhibited fewer individual FN risk-factors than patients with 
other cancers (Table 1). Breast cancer patients tended to be younger, have better Eastern 
Cooperative Oncology Group (ECOG) performance status scores, be receiving first-line 
chemotherapy, and have less advanced disease and fewer comorbidities than the other 
tumour types. SCLC patients were more likely to be female, have cardiovascular 
comorbidities, poorer ECOG scores and more advanced disease than NSCLC patients. 
 
 
Patient demographics by tumour type and G-CSF use 
in ECOG scores (score of 0-1 in 96% of breast cancer and 74% of SCLC patients). 
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Differences were observed in baseline characteristics between the overall G-CSF use groups 
(Table 2). Breast cancer patients receiving PP were less likely to have ongoing 
cardiovascular comorbidities, advanced disease, and prior chemotherapy and/or 
radiotherapy than those not receiving PP. For the other tumour types, differences between 
G-CSF subgroups were less clear due to smaller patient numbers. 
 
 
 
 
Received chemotherapy regimen and associated FN risk by tumour type 
 
Breast cancer patients were substantially more likely than patients with other tumours to 
receive a high FN-risk regimen (Figure 2). Although not all breast cancer patients who 
received a high-risk regimen were given G-CSF PP, the G-CSF PP group was more likely to 
receive a high-risk regimen than the No PP group (Table 2). Ovarian cancer patients were 
more likely than other tumour groups to receive a low-risk regimen. Many patients across 
all tumour types received a non-standard “other” regimen (Figure 2). 
 
 
In breast and SCLC, patients who did not receive a high FN-risk regimen were older than 
those who received a high-risk regimen: in breast cancer the median age was 50 years in 
>20% risk regimens, 51 years in 10-20% risk regimens, and 54 years in <10% risk 
regimens; in SCLC the corresponding median ages were 57, 61, and 60 years, respectively. 
Additionally, patients who did not receive a high FN-risk regimen had poorer ECOG 
performance scores: in breast cancer an ECOG score 0-1 was found in 98% of patients 
receiving >20% risk regimens, 95% of patients receiving 10-20% risk regimens, and 92% 
of patients receiving <10% risk regimens; in SCLC the corresponding proportions were 
100%, 77%, and 0%, respectively. No high-risk regimens were administered to NSCLC or 
ovarian cancer patients. Patients who received non-standard “other” chemotherapy for 
whom the FN risk could not be determined were older than those who received high-risk 
chemotherapy (median age 69 years in breast cancer and 64 years in SCLC) with variability 
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G-CSF use 
 
In the prespecified analysis of overall G-CSF use, less than half of the patients overall 
(43%) received G-CSF PP (Table 3a). G-CSF PP use was highest in breast cancer patients 
(55%), followed by SCLC patients (32%), and lowest in ovarian and NSCLC patients (both 
20%). Fewer breast cancer patients received no G-CSF at all (21%) than patients with other 
tumour types. G-CSF SP use was approximately 20% in each tumour group and few 
patients received G-CSF as treatment. 
 
 
 
 
Pegfilgrastim was the most commonly prescribed G-CSF in patients given PP, administered 
to 49%−86% of patients receiving PP in different tumour types and to 82% of PP patients 
overall. Daily G-CSF was given to 16% of patients who received PP, with a mean (±SD) 
number of days of G-CSF per cycle: breast, 4.88 (1.84); NSCLC, 3.95 (1.18); SCLC, 4.95 
(1.31); ovarian, 3.67 (1.63). In breast cancer, pegfilgrastim PP was maintained for a 
greater number of continuous cycles than daily G-CSF PP: pegfilgrastim PP was maintained 
until the fourth cycle in 95% of patients and until the sixth cycle in 89% of patients; daily 
G-CSF PP was maintained until the fourth cycle in 62% of patients and until the sixth cycle 
in 56% of patients. 
 
 
In a post-hoc analysis of overall G-CSF use, on-schedule G-CSF PP was more common in 
breast cancer patients than other tumour types, and use of not on-schedule G-CSF PP was 
similar across tumour groups (Table 3b). However, the proportion of patients who met the 
definition of on-schedule PP (29% in total) was lower than the proportion who met the 
prespecified G-CSF PP definition (43% in total) [compare Table 3b with 3a]. 
 
 
Neutropenia-related outcomes 
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A higher proportion of breast cancer patients achieved ≥85% RDI (86%) than did those 
with ovarian cancer (69%), SCLC (66%), or NSCLC (59%). Systemic anti-infectives were 
used in the study by 39% of SCLC, 26% of breast cancer, 21% of NSCLC, and 15% of 
ovarian cancer patients. 
 
 
Febrile neutropenia 
 
FN occurred in 127 patients overall (9%, 95%: CI 8, 11). Across all tumour types, FN 
incidence in all chemotherapy cycles ranged from 8−15%. FN occurred in cycle 1 in 77 
patients (6%, 95%: CI 4, 7), and for breast or lung cancer patients experiencing FN, their 
first FN episode occurred during cycle 1 in at least half of cases (Figure 3a). FN incidence 
was higher among patients with SCLC than those with NSCLC. As described above, patient 
baseline characteristic and chemotherapy regimens differed between G-CSF use groups 
(using the prespecified definitions of G-CSF use). Patients who received G-CSF PP were at 
greater risk of FN—due to more individual risk factors and/or higher chemotherapy FN risk— 
than those who did not receive G-CSF PP, meaning comparisons of FN incidence between 
these groups will be confounded. In patients receiving G-CSF PP, FN across all cycles was 
most common in SCLC (SCLC 8/44, 18%; NSCLC 4/45, 9%; breast 42/457, 9%; ovarian 
0/31, 0%). In patients not receiving G-CSF PP, FN across all cycles was also more common 
in SCLC (SCLC 12/93, 13%; ovarian 12/126, 10%; breast 35/372, 9%; NSCLC 14/179, 
8%). 
 
Of the 127 patients who experienced FN, 35% were receiving on-schedule G-CSF in the 
cycle in which their first FN event occurred. The first FN event occurred in a cycle not 
supported with on-schedule G-CSF in a majority of patients across all tumour types (Figure 
3b). 
 
In addition, 39% of the 127 patients who experienced FN were not given on-schedule G-CSF 
 
prophylaxis in the cycle after the first FN event occurred. 
12  
Discussion 
 
The primary study objective was to describe FN incidence based on tumour type and G-CSF 
use, in patients with solid tumours receiving myelotoxic chemotherapy and assessed by 
their physician to be at high risk of FN. To fully understand the study outcomes, certain 
considerations related to the observational study design must be acknowledged. Physician 
discretion was used to determine overall FN risk at study entry, which may have led to 
overestimation of FN risk and the inclusion of patients for whom the true FN risk was <20%. 
 
In addition, patient selection led to differences in baseline characteristics between the PP 
and No PP G-CSF subgroups. This was most evident in breast cancer, where patients 
administered G-CSF PP were less likely to have patient-related FN risk-factors and more 
likely to have received and completed a chemotherapy regimen associated with a high FN 
risk. These plus other differences between PP and No PP patients may confound 
comparisons of outcomes between G-CSF subgroups. 
 
 
Nonetheless, the results of this large study of routine clinical practice provide important 
insights into FN risk-assessment and subsequent neutropenia management. We observed 
notable differences in chemotherapy-related FN risk and individual FN risk-factors among 
patients assessed by physicians to be at high overall FN-risk. Breast cancer patients were 
relatively young with earlier-stage disease than patients with lung or ovarian cancer; they 
were more likely to complete their chemotherapy course and receive a standard regimen 
associated with a high FN-risk and at a RDI of ≥85%. These findings suggest physicians 
placed greater emphasis on individual risk-factors when assessing FN-risk in patients with 
lung or ovarian cancer than those with breast cancer, where assessment of high FN-risk was 
more likely to be driven by the choice of chemotherapy. The list of regimens included in 
guidelines is not exhaustive or conclusive(14-18) and the assignment of FN risk to a 
chemotherapy regimen was not possible in approximately 40% of cases (Figure 2), due to 
the use of non-standard regimens or variations to standard regimens for which we were 
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unable to find published data regarding the FN risk; this highlights the complexity faced by 
physicians when evaluating conflicting reports in the guidelines, published literature, and 
expert opinion. Despite the study inclusion criteria, a regimen estimated to have an FN risk 
≥20% was planned in, at most, one-third of patients. Hence, individual risk factors were 
probably used to determine an FN risk ≥20% in a large number of patients. This provides 
further evidence that fully-validated risk-models are needed to improve risk-assessment in 
patients receiving regimens for which the FN risk is <20% or unknown.(22-24) The complexity 
of FN risk-assessment may partly explain why patients with apparently low-risk regimens 
were enrolled in the study, and why guidelines were not fully implemented such that not all 
patients received G-CSF PP, particularly those with lung and ovarian cancer. 
 
 
Despite physician-assessment of high overall FN risk, a substantial number of patients (45– 
 
80%, Table 3a) did not receive G-CSF PP as recommended by current guidelines(14-18) Other 
studies of clinical practice have also reported poor guideline adherence in high-risk patients 
with NHL and solid tumours(25-28). It is clear from the current and previously published 
studies that patients at greater risk of FN are more likely to be selected for G-CSF PP. 
Results from breast cancer patients in the current study showed that more than half of 
those given G-CSF PP received a high FN-risk regimen and they were younger with fewer 
comorbidities and less advanced disease than those not given G-CSF PP. This suggests 
breast cancer patients selected for PP G-CSF were more likely to receive chemotherapy with 
curative intent, although treatment intent was not captured in the study. Few or none of the 
patients with other tumour types received a chemotherapy regimen associated with a high 
FN-risk, and the differences in individual risk factors were quite variable between the G-CSF 
PP and No PP groups. These results suggest that individual risk factors carry less weight 
than the regimen risk when physicians decide whether to provide G-CSF PP. 
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Post-hoc analyses were conducted to gain further insights into G-CSF prescribing patterns, 
using definitions of on-schedule prophylaxis that required administration within a 
therapeutically optimal window of 1-3 days after chemotherapy and for all subsequent 
cycles. This definition is more closely aligned with the approved product labelling 
instructions and guidelines.(14-18,20,21) Moreover, the on-schedule definition is supported by 
clinical evidence: the phase 3 registrational studies used the ~24 hours after chemotherapy 
schedule(12,13) and a comparison of same-day versus next-day pegfilgrastim dosing in breast 
cancer and NHL patients suggested administration 24 hours after chemotherapy provided 
better efficacy, although differences were not statistically significant.(29) Clinical data also 
supports G-CSF as prophylaxis given no later than 3 days after chemotherapy, with 
conflicting results as to whether 1-day or 3-days after chemotherapy is superior.(30,31) 
Although the FN-risk is greatest in the first cycle, the risk continues in subsequent 
cycles(32,32) and patients should be supported equally in all cycles during which they are at 
high risk. Results of the prespecified analysis used clinical practice-based definitions of G- 
CSF prophylaxis; however, as might be expected with the narrower post-hoc definitions, a 
smaller proportion of patients met the definition of receiving on-schedule G-CSF PP.  These 
findings indicate that current guidelines are not fully understood or implemented by all 
physicians, and may indicate a related need for education. Several clinical studies have 
shown FN rates to be halved among patients with solid tumours and lymphomas.(34,35) The 
current study supports these findings, with breast cancer patients more likely to receive 
myelosuppressive chemotherapy and G-CSF PP than patients with lung or ovarian cancer, 
but experiencing similar or lower FN rates. 
 
 
Compared with daily G-CSFs, pegfilgrastim PP has been shown to lower FN rates by 
approximately one-third.(35-37) In the current study, pegfilgrastim was more commonly used 
for PP than daily G-CSF. Furthermore, in breast cancer, pegfilgrastim PP was maintained 
over a greater number of cycles than filgrastim. Across all tumour types, the number of 
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days of daily G-CSF was lower than recommended, possibly due to the later chemotherapy 
lines received by patients with lung or ovarian cancer.(14–18) 
 
 
Results from the primary analysis show that patients from all tumour types were at risk of 
FN, and, except for patients with ovarian cancer, the risk was greatest in the first cycle as 
observed in other studies(13,32,33). Furthermore, the highest incidence of FN occurred in SCLC 
(15% overall and 12% in cycle 1) despite the relatively low use of high-risk regimens. Since 
less than one-third of all SCLC patients were supported with G-CSF PP (and less than one- 
fifth received on-schedule PP), the need for increased awareness of FN risk appears 
particularly great in this population. 
 
 
It was apparent that only a minority of patients (35%) who experienced FN were receiving 
on-schedule G-CSF support at the time of their first FN event. In addition, a higher 
proportion of patients than anticipated (39%) did not receive G-CSF prophylaxis in the cycle 
after the first FN occurred. An FN episode can have severe implications for both patients and 
healthcare systems: FN frequently results in hospitalization with in-hospital mortality rates 
of up to 10% reported.(8) Despite the potential impact of FN, other than recommended 
 
administration or even complete lack of G-CSF was frequently observed in the study. 
Physicians may have selected other strategies for FN risk-reduction such as using 
prophylactic antibiotics, shorter courses of daily G-CSF than recommended, or modifying or 
reducing the intensity of the standard chemotherapy regimen. Antibiotic prophylaxis 
 
reduces the risk of infection and infection-related complications (38,39); it has no effect on the 
underlying neutropenia. In breast cancer patients undergoing TAC chemotherapy, antibiotics 
and shorter than recommended courses of daily G-CSF have both been shown to provide 
suboptimal protection against FN, particularly in comparison to pegfilgrastim.(37) Overall, 
insufficient evidence is available to make a valid comparison between antibiotic prophylaxis 
and G-CSF use.(39) Recent ASCO guidelines recommend that antibiotic prophylaxis should be 
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limited to only those patients expected to experience long-lasting very severe 
 
neutropenia.(40) The potential for development of antibiotic resistance should be considered 
in clinical decision making. Reductions or changes to the chemotherapy regimen should be 
considered when treatment intent is palliative,(15) but reductions in dose intensity may 
compromise long-term outcomes in patients receiving potentially curative chemotherapy (7). 
This study indicates that improved education of physicians on all aspects of neutropenia 
management may enable more fully-informed treatment decisions and improved outcomes 
in patients with cancer receiving myelotoxic chemotherapy. 
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Tables 
 
Table 1. Baseline demographics by tumour type 
 
  
 
Breast 
 
(N=829) 
 
 
NSCLC 
(N=224) 
 
 
SCLC 
(N=137) 
 
 
Ovarian 
 
(N=157) 
Age, mean ± SD years 53.1±10.9 62.3±9.0 62.1±8.8 60.5±11.6 
 
Age ≥65 years, n (%) 
 
136 (16) 
 
96 (43) 
 
51 (37) 
 
71 (45) 
 
Female, n (%) 
 
821 (99) 
 
50 (22) 
 
44 (32) 
 
157 (100) 
 
ECOG 0–1, n (%) 
 
800 (97) 
 
187 (83) 
 
104 (76) 
 
129 (82) 
 
Advanced stage,a n (%) 
 
90 (11) 
 
126 (56) 
 
98 (72) 
 
122 (78) 
 
Prior CT and/or RT, n (%) 
 
Specific comorbidities,b n 
 
41 (5) 
 
59 (26) 
 
35 (26) 
 
34 (22) 
 
(%) 
    
 
Any comorbidity 
 
247 (30) 
 
121 (54) 
 
73 (53) 
 
70 (45) 
 
Cardiovascular 
 
101 (41) 
 
64 (53) 
 
44 (60) 
 
37 (53) 
 
Respiratory 
 
24 (10) 
 
47 (39) 
 
27 (37) 
 
5 (7) 
 
Hepatic/biliary 
 
7 (3) 
 
2 (2) 
 
3 (4) 
 
3 (4) 
 
Renal 
 
4 (2) 
 
4 (3) 
 
2 (3) 
 
5 (7) 
CT, chemotherapy; RT, radiotherapy. 
 
aBreast cancer and NSCLC, stage IV; SCLC, extensive; ovarian, stage III–IV. bDerived from 
medical history records, percentages calculated from number of patients with any 
comorbidity. 
  
 
 
 
Table 2. Baseline demographics by tumour type by G-CSF PP use 
 
Breast NSCLC SCLC Ovarian 
 
 PP 
(N=457) 
No PP 
(N=372) 
PP 
(N=45) 
No PP 
(N=179) 
PP 
(N=44) 
No PP 
(N=93) 
PP 
(N=31) 
No PP 
(N=126) 
Age, mean ± SD years 52.3 54.2 62.6 62.3 62.6 61.9 62.1 60.1 
 ±10.9 ±10.9 ±8.7 ±9.1 ±10.2 ±8.0 ±12.0 ±11.5 
Age ≥65 years, n (%) 67 (15) 69 (19) 20 (44) 76 (42) 19 (43) 32 (34) 15 (48) 56 (44) 
Female, n (%) 453 (99) 368 (99) 13 (29) 37 (21) 12 (27) 32 (34) 31 (100) 126 (100) 
ECOG 0–1, n (%) 447 (98) 353 (95) 33 (73) 154 (86) 35 (80) 69 (74) 28 (90) 101 (80) 
Advanced stage disease,a n (%) 39 (9) 51 (14) 29 (64) 97 (54) 28 (64) 70 (75) 22 (71) 100 (80) 
Prior CT and/or RT, n (%) 
 
Specific comorbidities,b n (%) 
15 (3) 26 (7) 10 (22) 49 (27) 11 (25) 24 (26) 9 (29) 25 (20) 
Cardiovascular 45 (10) 56 (15) 10 (22) 46 (26) 14 (32) 24 (26) 4 (13) 36 (29) 
Respiratory 10 (2) 10 (3) 5 (11) 31 (17) 9 (20) 14 (15) 0 (0) 2 (2) 
Hepatic/biliary 2 (<1) 2 (<1) 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 2 (2) 
Renal 2 (<1) 0 (0) 0 (0) 3 (2) 0 (0) 0 (0) 0 (0) 4 (3) 
 
Chemotherapy risk, n (%) 
        
<10% 25 (5) 66 (18) 5 (11) 25 (14) 0 (0) 1 (1) 7 (23) 47 (37) 
10 to <20% 31 (7) 26 (7) 13 (29) 47 (26) 17 (39) 39 (42) 7 (23) 1 (1) 
≥20% 246 (54) 136 (37) 0 (0) 0 (0) 2 (5) 4 (4) 0 (0) 0 (0) 
Other/unknown 155 (34) 144 (39) 27 (60) 107 (60) 25 (57) 49 (53) 17 (55) 78 (62) 
CT, chemotherapy; RT, radiotherapy. aBreast cancer and NSCLC, stage IV; SCLC, extensive; ovarian, stage III–IV. bDerived 
 
from medical history records marked as current or continuing and with relevant system organ class. 
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Table 3. Overall G-CSF use by tumour type. (a) Prespecified analysis of G-CSF use. (b) Post 
hoc analysis based on the more stringent definitions of G-CSF prophylaxis and requirement 
for continued G-CSF prophylaxis in subsequent cycles after first use. 
(a) 
 
 
 
 
 
 
n (%) 
 
 
Breast 
 
N=829 
 
 
NSCLC 
N=224 
 
 
SCLC 
N=137 
 
 
Ovarian 
 
N=157 
 
 
Total 
 
N=1347 
PP 457 (55) 45 (20) 44 (32) 31 (20) 557 (43) 
 
SP 
 
176 (21) 
 
41 (18) 
 
28 (20) 
 
30 (19) 
 
275 (20) 
 
G-CSF treatment only 
 
21 (3) 
 
18 (8) 
 
9 (7) 
 
14 (9) 
 
62 (5) 
 
No G-CSF 
 
175 (21) 
 
120 (54) 
 
56 (41) 
 
82 (52) 
 
433 (32) 
 
 
(b) 
     
 
 
 
 
 
n (%) 
 
 
Breast 
 
N=829 
 
 
NSCLC 
N=224 
 
 
SCLC 
N=137 
 
 
Ovarian 
 
N=157 
 
 
Total 
 
N=1347 
On-schedule PP 322 (39) 24 (11) 26 (19) 23 (15) 395 (29) 
 
Not on-schedule PP 
 
332 (40) 
 
80 (36) 
 
55 (40) 
 
52 (33) 
 
519 (39) 
 
No G-CSF 
 
175 (21) 
 
120 (54) 
 
56 (41) 
 
82 (52) 
 
433 (32) 
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Figures 
 
Captions 
 
 
 
 
Figure 1 – Patient disposition. CT = chemotherapy. 
 
 
 
 
Figure 2 - Planned chemotherapy regimens and estimated FN risk 
 
Chemotherapy FN risk assessment was determined by a post-hoc clinical review of 
established guidelines and published literature. Data were not available for 2 patients 
(NSCLC and ovarian). FN risk could not be defined for regimens recorded as “other”; 
regimens which are not routinely used or variations to standard regimens and for which 
there were no published data regarding FN risk. Breast cancer, >20% n = 382 (AC-Doc, 
ADoc, APac dd AC-Pac, DocAC(TAC), DocEC, EC-Doc, EDoc, FEC-Doc), 10-20% n = 57 
(Doc100, DocC, DocPLD, EPac, FEC90), <10% n = 91 (AC, AC-Pac, A-Pac, CarboPac, CMF, 
CycloPLD, EC, EC-Pac, FAC, FEC-Pac, Paclitaxel); NSCLC >20% n = 0, 10-20% n =60 
(CarboDoc, CarboVin, CisDoc, CisEto [q3W], CisVin, Doc75), <10% n = 30 (CarboGem, 
CarboPac, CisGem, CisPem, Gem, MIC); SCLC, >20% n = 6 (CDE[ACE], Topotecan), 10- 
20% n = 56 (CarboDoc, CarboEto, CisEto[q4W], Doc75), <10% n = 1 (CarboPac); Ovarian, 
 
>20% n = 0, 10-20% n = 8 (CarboDoc, Topotecan), <10% n = 54 (CarboMono, CarboPac, 
CarboPLD, CisPac, Gem, Pac, PLD). Chemotherapy regimens:) A, doxorubicin; Carbo, 
carboplatin; Cis, cisplatin; C, cyclophosphamide; dd, dose-dense; Doc, docetaxel; E, 
epirubicin; Etop etoposide; F, fluorouracil; Gem, gemcitabine; M, methotrexate; Pac, 
paclitaxel; Pem, pemetrexed; PLD, pegylated liposomal doxorubicin; T, paclitaxel; Vin, 
vinorelbine. 
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Figure 3 - Incidence of FN by tumour group. (a) Incidence of FN in cycles 1–8 and in cycle 1 
 
Any: Cycles 1–8; C1: cycle 1. (b) G-CSF use at the time of the first FN event, grouped 
according to the post hoc definitions of on-schedule G-CSF use: On-schedule prophylaxis 
consists of patients who received on-schedule G-CSF in continuous cycles from the cycle in 
which it was first administered up to and including the cycle in which the first FN occurred. 
No G-CSF consists of patients who had received no G-CSF up to the time of FN. Not on- 
schedule G-CSF consists of the remaining patients – ie, those who had received some G-CSF 
but did not receive on-schedule G-CSF in the cycle in which the first FN event occurred. 
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Fig. 1  
Patients enrolled 
(N = 1370) 
 
 
 
23 (2%) excluded from the full 
analysis set 
8 did not receive chemotherapy 
3 had missing or predicted FN risk 
<20% 
2 with concurrent radiotherapy 
1 not diagnosed with ovarian, lung, 
or breast cancer 
9 other 
 
Full analysis set 
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